Inhibition of HIV-1 gene transcription by KAP1 in myeloid lineage.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
29 01 2021
Historique:
received: 05 06 2020
accepted: 13 01 2021
entrez: 30 1 2021
pubmed: 31 1 2021
medline: 16 11 2021
Statut: epublish

Résumé

HIV-1 latency generates reservoirs that prevent viral eradication by the current therapies. To find strategies toward an HIV cure, detailed understandings of the molecular mechanisms underlying establishment and persistence of the reservoirs are needed. The cellular transcription factor KAP1 is known as a potent repressor of gene transcription. Here we report that KAP1 represses HIV-1 gene expression in myeloid cells including microglial cells, the major reservoir of the central nervous system. Mechanistically, KAP1 interacts and colocalizes with the viral transactivator Tat to promote its degradation via the proteasome pathway and repress HIV-1 gene expression. In myeloid models of latent HIV-1 infection, the depletion of KAP1 increased viral gene elongation and reactivated HIV-1 expression. Bound to the latent HIV-1 promoter, KAP1 associates and cooperates with CTIP2, a key epigenetic silencer of HIV-1 expression in microglial cells. In addition, Tat and CTIP2 compete for KAP1 binding suggesting a dynamic modulation of the KAP1 cellular partners upon HIV-1 infection. Altogether, our results suggest that KAP1 contributes to the establishment and the persistence of HIV-1 latency in myeloid cells.

Identifiants

pubmed: 33514850
doi: 10.1038/s41598-021-82164-w
pii: 10.1038/s41598-021-82164-w
pmc: PMC7846785
doi:

Substances chimiques

BCL11B protein, human 0
Repressor Proteins 0
Tumor Suppressor Proteins 0
tat Gene Products, Human Immunodeficiency Virus 0
TRIM28 protein, human EC 2.3.2.27
Tripartite Motif-Containing Protein 28 EC 2.3.2.27

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2692

Références

Kumar, A., Abbas, W. & Herbein, G. HIV-1 latency in monocytes/macrophages. Viruses 6, 1837–1860 (2014).
pubmed: 24759213 pmcid: 4014723 doi: 10.3390/v6041837
Kandathil, A. J., Sugawara, S. & Balagopal, A. Are T cells the only HIV-1 reservoir?. Retrovirology 13, 86 (2016).
pubmed: 27998285 pmcid: 5175311 doi: 10.1186/s12977-016-0323-4
Honeycutt, J. B. et al. HIV persistence in tissue macrophages of humanized myeloid-only mice during antiretroviral therapy. Nat. Med. 23, 638–643 (2017).
pubmed: 28414330 pmcid: 5419854 doi: 10.1038/nm.4319
Gelman, B. B. et al. Neurovirological correlation with HIV-associated neurocognitive disorders and encephalitis in a HAART-era cohort. J. Acquir. Immune Defic. Syndr. 62, 487–495 (2013).
pubmed: 23242157 pmcid: 3664102 doi: 10.1097/QAI.0b013e31827f1bdb
Clements, J. E., Gama, L., Graham, D. R., Mankowski, J. L. & Zink, M. C. A simian immunodeficiency virus macaque model of highly active antiretroviral treatment: Viral latency in the periphery and the central nervous system. Curr. Opin. HIV AIDS 6, 37–42 (2011).
pubmed: 21242892 pmcid: 3215305 doi: 10.1097/COH.0b013e3283412413
Llewellyn, G. N., Alvarez-Carbonell, D., Chateau, M., Karn, J. & Cannon, P. M. HIV-1 infection of microglial cells in a reconstituted humanized mouse model and identification of compounds that selectively reverse HIV latency. J. Neurovirol. 24, 192–203 (2018).
pubmed: 29256041 doi: 10.1007/s13365-017-0604-2
Le Douce, V., Cherrier, T., Riclet, R., Rohr, O. & Schwartz, C. The Many lives of CTIP2: From AIDS to cancer and cardiac hypertrophy. J. Cell. Physiol. 229, 533–537 (2014).
pubmed: 24122342 doi: 10.1002/jcp.24490
Le Douce, V. et al. HIC1 controls cellular- and HIV-1-gene transcription via interactions with CTIP2 and HMGA1. Sci. Rep. 6, 34920 (2016).
pubmed: 27725726 pmcid: 5057145 doi: 10.1038/srep34920
Marban, C. et al. Recruitment of chromatin-modifying enzymes by CTIP2 promotes HIV-1 transcriptional silencing. EMBO J. 26, 412–423 (2007).
pubmed: 17245431 pmcid: 1783449 doi: 10.1038/sj.emboj.7601516
Le Douce, V. et al. LSD1 cooperates with CTIP2 to promote HIV-1 transcriptional silencing. Nucleic Acids Res. 40, 1904–1915 (2012).
pubmed: 22067449 doi: 10.1093/nar/gkr857
Rohr, O. et al. Recruitment of tat to heterochromatin protein HP1 via interaction with CTIP2 inhibits human immunodeficiency virus type 1 replication in microglial cells. J Virol 77, 5415–5427 (2003).
pubmed: 12692243 pmcid: 153947 doi: 10.1128/JVI.77.9.5415-5427.2003
Cherrier, T. et al. CTIP2 is a negative regulator of P-TEFb. Proc. Natl. Acad. Sci. U.S.A. 110, 12655–12660 (2013).
pubmed: 23852730 pmcid: 3732990 doi: 10.1073/pnas.1220136110
Eilebrecht, S. et al. HMGA1 recruits CTIP2-repressed P-TEFb to the HIV-1 and cellular target promoters. Nucleic Acids Res. 42, 4962–4971 (2014).
pubmed: 24623795 pmcid: 4005653 doi: 10.1093/nar/gku168
Desplats, P. et al. Molecular and pathologic insights from latent HIV-1 infection in the human brain. Neurology 80, 1415–1423 (2013).
pubmed: 23486877 pmcid: 3662272 doi: 10.1212/WNL.0b013e31828c2e9e
Moosmann, P., Georgiev, O., Le Douarin, B., Bourquin, J. P. & Schaffner, W. Transcriptional repression by RING finger protein TIF1 beta that interacts with the KRAB repressor domain of KOX1. Nucleic Acids Res. 24, 4859–4867 (1996).
pubmed: 9016654 pmcid: 146346 doi: 10.1093/nar/24.24.4859
Iyengar, S. & Farnham, P. J. KAP1 Protein: An enigmatic master regulator of the genome. J Biol Chem 286, 26267–26276 (2011).
pubmed: 21652716 pmcid: 3143589 doi: 10.1074/jbc.R111.252569
Iyengar, S., Ivanov, A. V., Jin, V. X., Rauscher, F. J. & Farnham, P. J. Functional analysis of KAP1 genomic recruitment. Mol. Cell. Biol. 31, 1833–1847 (2011).
pubmed: 21343339 pmcid: 3133220 doi: 10.1128/MCB.01331-10
Liang, Q. et al. Tripartite motif-containing protein 28 is a small ubiquitin-related modifier E3 ligase and negative regulator of IFN regulatory factor 7. J. Immunol. 187, 4754–4763 (2011).
pubmed: 21940674 doi: 10.4049/jimmunol.1101704
Riclet, R. et al. Disruption of the interaction between transcriptional intermediary factor 1β and heterochromatin protein 1 leads to a switch from DNA hyper- to hypomethylation and H3K9 to H3K27 trimethylation on the MEST promoter correlating with gene reactivation. Mol Biol Cell 20, 296–305 (2009).
pubmed: 18923144 pmcid: 2613122 doi: 10.1091/mbc.e08-05-0510
Yang, Y. et al. Acetylated hsp70 and KAP1-mediated Vps34 SUMOylation is required for autophagosome creation in autophagy. Proc. Natl. Acad. Sci. U.S.A. 110, 6841–6846 (2013).
pubmed: 23569248 pmcid: 3637746 doi: 10.1073/pnas.1217692110
Garvin, A. J. et al. The deSUMOylase SENP7 promotes chromatin relaxation for homologous recombination DNA repair. EMBO Rep. 14, 975–983 (2013).
pubmed: 24018422 pmcid: 3818072 doi: 10.1038/embor.2013.141
Groh, S. & Schotta, G. Silencing of endogenous retroviruses by heterochromatin. Cell Mol. Life Sci. 74, 2055–2065 (2017).
pubmed: 28160052 doi: 10.1007/s00018-017-2454-8
Allouch, A. et al. The TRIM family protein KAP1 Inhibits HIV-1 integration. Cell Host Microbe 9, 484–495 (2011).
pubmed: 21669397 doi: 10.1016/j.chom.2011.05.004
Nishitsuji, H., Abe, M., Sawada, R. & Takaku, H. ZBRK1 represses HIV-1 LTR-mediated transcription. FEBS Lett. 586, 3562–3568 (2012).
pubmed: 22975076 doi: 10.1016/j.febslet.2012.08.010
Nishitsuji, H., Sawada, L., Sugiyama, R. & Takaku, H. ZNF10 inhibits HIV-1 LTR activity through interaction with NF-κB and Sp1 binding motifs. FEBS Lett. 589, 2019–2025 (2015).
pubmed: 26096782 doi: 10.1016/j.febslet.2015.06.013
McNamara, R. P. et al. KAP1 recruitment of the 7SK snRNP complex to promoters enables transcription elongation by RNA polymerase II. Mol. Cell 61, 39–53 (2016).
pubmed: 26725010 doi: 10.1016/j.molcel.2015.11.004
Morton, E. L. et al. Transcriptional circuit fragility influences HIV proviral fate. Cell Rep. 27, 154-171.e9 (2019).
pubmed: 30943398 pmcid: 6461408 doi: 10.1016/j.celrep.2019.03.007
Lee, A., CingÖz, O., Sabo, Y. & Goff, S. P. Characterization of interaction between Trim28 and YY1 in silencing proviral DNA of Moloney murine leukemia virus. Virology 516, 165–175 (2018).
pubmed: 29407374 doi: 10.1016/j.virol.2018.01.012
Wolf, D. & Goff, S. P. Embryonic stem cells use ZFP809 to silence retroviral DNAs. Nature 458, 1201–1204 (2009).
pubmed: 19270682 pmcid: 2676211 doi: 10.1038/nature07844
Taura, M., Song, E., Ho, Y.-C. & Iwasaki, A. Apobec3A maintains HIV-1 latency through recruitment of epigenetic silencing machinery to the long terminal repeat. Proc. Natl. Acad. Sci. U.S.A. 116, 2282–2289 (2019).
pubmed: 30670656 pmcid: 6369738 doi: 10.1073/pnas.1819386116
Ma, X. et al. TRIM28 promotes HIV-1 latency by SUMOylating CDK9 and inhibiting P-TEFb. Elife 8, e42426 (2019).
pubmed: 30652970 pmcid: 6361614 doi: 10.7554/eLife.42426
Wires, E. S. et al. Methamphetamine activates nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and induces human immunodeficiency virus (HIV) transcription in human microglial cells. J. Neurovirol. 18, 400–410 (2012).
pubmed: 22618514 pmcid: 3469781 doi: 10.1007/s13365-012-0103-4
Kutsch, O., Benveniste, E. N., Shaw, G. M. & Levy, D. N. Direct and quantitative single-cell analysis of human immunodeficiency virus type 1 reactivation from latency. J. Virol. 76, 8776–8786 (2002).
pubmed: 12163598 pmcid: 136999 doi: 10.1128/JVI.76.17.8776-8786.2002
Meylan, S. et al. A gene-rich, transcriptionally active environment and the pre-deposition of repressive marks are predictive of susceptibility to KRAB/KAP1-mediated silencing. BMC Genomics 12, 378 (2011).
pubmed: 21791101 pmcid: 3199781 doi: 10.1186/1471-2164-12-378
Ryan, R. F. et al. KAP-1 corepressor protein interacts and colocalizes with heterochromatic and euchromatic HP1 proteins: a potential role for Krüppel-associated box-zinc finger proteins in heterochromatin-mediated gene silencing. Mol. Cell. Biol. 19, 4366–4378 (1999).
pubmed: 10330177 pmcid: 104396 doi: 10.1128/MCB.19.6.4366
Coiras, M. et al. Modifications in the human T cell proteome induced by intracellular HIV-1 Tat protein expression. Proteomics 6, S63–S73 (2006).
pubmed: 16526095 doi: 10.1002/pmic.200500437
Ruben, S. et al. Structural and functional characterization of human immunodeficiency virus tat protein. J. Virol. 63, 1–8 (1989).
pubmed: 2535718 pmcid: 247650 doi: 10.1128/jvi.63.1.1-8.1989
Ali, A. & Banerjea, A. C. Curcumin inhibits HIV-1 by promoting Tat protein degradation. Sci Rep 6, 27539 (2016).
pubmed: 27283735 pmcid: 4901322 doi: 10.1038/srep27539
Balachandran, A. et al. Identification of small molecule modulators of HIV-1 Tat and Rev protein accumulation. Retrovirology 14, 7 (2017).
pubmed: 28122580 pmcid: 5267425 doi: 10.1186/s12977-017-0330-0
Gargano, B., Fiorillo, M., Amente, S., Majello, B. & Lania, L. p14ARF is capable of promoting HIV-1 tat degradation. Cell Cycle 7, 1433–1439 (2008).
pubmed: 18418067 doi: 10.4161/cc.7.10.5878
Hong, H.-W., Lee, S.-W. & Myung, H. Induced degradation of Tat by nucleocapsid (NC) via the proteasome pathway and its effect on HIV transcription. Viruses 5, 1143–1152 (2013).
pubmed: 23611845 pmcid: 3705270 doi: 10.3390/v5041143
Li, J. et al. Long noncoding RNA NRON contributes to HIV-1 latency by specifically inducing tat protein degradation. Nat. Commun. 7, 11730 (2016).
pubmed: 27291871 pmcid: 4909936 doi: 10.1038/ncomms11730
Wan, Z. & Chen, X. Triptolide inhibits human immunodeficiency virus type 1 replication by promoting proteasomal degradation of Tat protein. Retrovirology 11, 88 (2014).
pubmed: 25323821 pmcid: 4205289 doi: 10.1186/s12977-014-0088-6
Sacco, A. et al. Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom’s Macroglobulinemia. Clin Cancer Res 17, 1753–1764 (2011).
pubmed: 21355079 doi: 10.1158/1078-0432.CCR-10-2130
Li, X. et al. Role for KAP1 serine 824 phosphorylation and sumoylation/desumoylation switch in regulating KAP1-mediated transcriptional repression. J. Biol. Chem. 282, 36177–36189 (2007).
pubmed: 17942393 doi: 10.1074/jbc.M706912200
Ivanov, A. V. et al. PHD domain-mediated E3 ligase activity directs intramolecular sumoylation of an adjacent bromodomain required for gene silencing. Mol. Cell 28, 823–837 (2007).
pubmed: 18082607 pmcid: 4348069 doi: 10.1016/j.molcel.2007.11.012
Cheng, C.-T., Kuo, C.-Y. & Ann, D. K. KAPtain in charge of multiple missions: Emerging roles of KAP1. World J Biol Chem 5, 308–320 (2014).
pubmed: 25225599 pmcid: 4160525 doi: 10.4331/wjbc.v5.i3.308
Cismasiu, V. B. et al. BCL11B is a general transcriptional repressor of the HIV-1 long terminal repeat in T lymphocytes through recruitment of the NuRD complex. Virology 380, 173–181 (2008).
pubmed: 18768194 doi: 10.1016/j.virol.2008.07.035
Schultz, D. C., Friedman, J. R. & Rauscher, F. J. Targeting histone deacetylase complexes via KRAB-zinc finger proteins: the PHD and bromodomains of KAP-1 form a cooperative unit that recruits a novel isoform of the Mi-2alpha subunit of NuRD. Genes Dev. 15, 428–443 (2001).
pubmed: 11230151 pmcid: 312636 doi: 10.1101/gad.869501
Quénet, D. et al. The histone subcode: poly(ADP-ribose) polymerase-1 (Parp-1) and Parp-2 control cell differentiation by regulating the transcriptional intermediary factor TIF1beta and the heterochromatin protein HP1alpha. FASEB J. 22, 3853–3865 (2008).
pubmed: 18676401 doi: 10.1096/fj.08-113464
Tomimatsu, N., Mukherjee, B. & Burma, S. Distinct roles of ATR and DNA-PKcs in triggering DNA damage responses in ATM-deficient cells. EMBO Rep. 10, 629–635 (2009).
pubmed: 19444312 pmcid: 2711839 doi: 10.1038/embor.2009.60
Cherrier, T. et al. p21(WAF1) gene promoter is epigenetically silenced by CTIP2 and SUV39H1. Oncogene 28, 3380–3389 (2009).
pubmed: 19581932 pmcid: 3438893 doi: 10.1038/onc.2009.193
Imai, K. et al. Cyclin T1 stabilizes expression levels of HIV-1 Tat in cells. FEBS J. 276, 7124–7133 (2009).
pubmed: 20064163 doi: 10.1111/j.1742-4658.2009.07424.x
Jin, X. et al. MAGE-TRIM28 complex promotes the Warburg effect and hepatocellular carcinoma progression by targeting FBP1 for degradation. Oncogenesis 6, e312 (2017).
pubmed: 28394358 pmcid: 5520498 doi: 10.1038/oncsis.2017.21
Okamoto, K., Kitabayashi, I. & Taya, Y. KAP1 dictates p53 response induced by chemotherapeutic agents via Mdm2 interaction. Biochem. Biophys. Res. Commun. 351, 216–222 (2006).
pubmed: 17056014 doi: 10.1016/j.bbrc.2006.10.022
Pineda, C. T. et al. Degradation of AMPK by a cancer-specific ubiquitin ligase. Cell 160, 715–728 (2015).
pubmed: 25679763 pmcid: 5629913 doi: 10.1016/j.cell.2015.01.034
Avram, D. & Califano, D. The multifaceted roles of Bcl11b in thymic and peripheral T cells - impact on immune diseases. J Immunol 193, 2059–2065 (2014).
pubmed: 25128552 doi: 10.4049/jimmunol.1400930
Czerwińska, P., Mazurek, S. & Wiznerowicz, M. The complexity of TRIM28 contribution to cancer. J Biomed Sci 24, 63 (2017).
pubmed: 28851455 pmcid: 5574234 doi: 10.1186/s12929-017-0374-4
Czerwińska, P. et al. TRIM28 multi-domain protein regulates cancer stem cell population in breast tumor development. Oncotarget 8, 863–882 (2017).
pubmed: 27845900 doi: 10.18632/oncotarget.13273
Hu, M. et al. Expression of KAP1 in epithelial ovarian cancer and its correlation with drug-resistance. Int. J. Clin. Exp. Med. 8, 17308–17320 (2015).
pubmed: 26770323 pmcid: 4694223
Wang, Y.-Y., Li, L., Zhao, Z.-S. & Wang, H.-J. Clinical utility of measuring expression levels of KAP1, TIMP1 and STC2 in peripheral blood of patients with gastric cancer. World J. Surg. Oncol. 11, 81 (2013).
pubmed: 23548070 pmcid: 3620905 doi: 10.1186/1477-7819-11-81
Janabi, N., Peudenier, S., Héron, B., Ng, K. H. & Tardieu, M. Establishment of human microglial cell lines after transfection of primary cultures of embryonic microglial cells with the SV40 large T antigen. Neurosci. Lett. 195, 105–108 (1995).
pubmed: 7478261 doi: 10.1016/0304-3940(94)11792-H

Auteurs

Amina Ait-Ammar (A)

Université de Strasbourg, UR 7292 DHPI, FMTS, IUT Louis Pasteur, 1 Allée d'Athènes, 67300, Schiltigheim, France.
Center for Research in Infectious Diseases (CRID), School of Medicine and Medical Science (SMMS), University College Dublin (UCD), Dublin, Ireland.
Service of Molecular Virology, Institute for Molecular Biology and Medicine (IBMM), Université Libre de Bruxelles (ULB), Gosselies, Belgium.

Maxime Bellefroid (M)

Service of Molecular Virology, Institute for Molecular Biology and Medicine (IBMM), Université Libre de Bruxelles (ULB), Gosselies, Belgium.

Fadoua Daouad (F)

Université de Strasbourg, UR 7292 DHPI, FMTS, IUT Louis Pasteur, 1 Allée d'Athènes, 67300, Schiltigheim, France.

Valérie Martinelli (V)

Laboratory Biology of the Nucleus, Institute for Molecular Biology and Medicine, Université Libre de Bruxelles, 6041, Charleroi, Belgium.

Jeanne Van Assche (J)

Université de Strasbourg, UR 7292 DHPI, FMTS, IUT Louis Pasteur, 1 Allée d'Athènes, 67300, Schiltigheim, France.

Clémentine Wallet (C)

Université de Strasbourg, UR 7292 DHPI, FMTS, IUT Louis Pasteur, 1 Allée d'Athènes, 67300, Schiltigheim, France.

Anthony Rodari (A)

Service of Molecular Virology, Institute for Molecular Biology and Medicine (IBMM), Université Libre de Bruxelles (ULB), Gosselies, Belgium.

Marco De Rovere (M)

Université de Strasbourg, UR 7292 DHPI, FMTS, IUT Louis Pasteur, 1 Allée d'Athènes, 67300, Schiltigheim, France.

Birthe Fahrenkrog (B)

Laboratory Biology of the Nucleus, Institute for Molecular Biology and Medicine, Université Libre de Bruxelles, 6041, Charleroi, Belgium.

Christian Schwartz (C)

Université de Strasbourg, UR 7292 DHPI, FMTS, IUT Louis Pasteur, 1 Allée d'Athènes, 67300, Schiltigheim, France.

Carine Van Lint (C)

Service of Molecular Virology, Institute for Molecular Biology and Medicine (IBMM), Université Libre de Bruxelles (ULB), Gosselies, Belgium. cvlint@ulb.ac.be.

Virginie Gautier (V)

Center for Research in Infectious Diseases (CRID), School of Medicine and Medical Science (SMMS), University College Dublin (UCD), Dublin, Ireland. virginie.gautier@ucd.ie.

Olivier Rohr (O)

Université de Strasbourg, UR 7292 DHPI, FMTS, IUT Louis Pasteur, 1 Allée d'Athènes, 67300, Schiltigheim, France. olivier.rohr@unistra.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH